The most recently published multicenter, open-label, phase 1a/b trial (NCT02660034) from Australia, investigated the safety and anti-tumor effects of pamiparib, an oral PARP1/2 inhibitor, combined with tislelizumab, a humanized anti-PD-1 monoclonal antibody, in patients with advanced solid tumors (60). The gene discussed is PARP1; the disease is neoplasm.